Product Description
An oral, dual target protein degrader specifically engineered to degrade GSPT1 and IKZF1/3 for patients with advanced hematologic and solid tumor malignancies. BTX-1188 is the first orally bioavailable, rationally designed dual target protein degrader, engineered to specifically degrade validated oncology targets GSPT1 and IKZF1/3. By degrading GSPT1 and IKZF1/3, BTX-1188’s profile is expected to be differentiated from protein degraders that exclusively target GSPT1. BioTheryX believes BTX-1188 has broad potential applicability in both hematologic and solid tumor malignancies and is currently studying the molecule in both settings as part of a Phase 1 clinical study. (Sourced from: https://biotheryx.com/biotheryx-doses-first-patient-in-phase-1-study-investigating-lead-protein-degrader-candidate-btx-1188/)
Mechanisms of Action: GSPT1 Degrader,IKZF3 Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioTheryX
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BTX-1188-001 | P1 |
Terminated |
Acute Myeloid Leukemia|Lymphoma |
2023-09-12 |
25% |